Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 530-532

  Tang, Lei ^a   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; POLYCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; MONOTHERAPY; NONHUMAN; OVARY CANCER; RABBIT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE; TUMOR CELL;

ANIMALS; ANTINEMATODAL AGENTS; ANTINEOPLASTIC PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOGLOBULINS; OVARIAN NEOPLASMS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

ORYCTOLAGUS CUNICULUS;

EID: 79952316971     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.009     Document Type: Article

References (28)

1. Liu B., Nash J., Runowicz C., Swede H., Stevens R., Li Z.H. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010, 3:7-17.
2. Ozols R.F. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002, 20(5):1161-1163.
3. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
4. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
5. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., Ebeling S.B. Complement-induced cell death by Rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006, 12(13):4027-4035.
6. Berek J., Taylor P., McGuire W., Smith L.M., Schultes B., Nicodemus C.F. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009, 27(3):418-425.
7. Ehlen T.G., Hoskins P.J., Miller D., et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005, 15(6):1023-1034.
8. Ray-Coquard I., Guastalla J.P., Allouache D., et al. HER2 overexpression/amplification and Trastuzumab treatment in advanced ovarian cancer: a GINECO phase II study. Clin Ovarian Cancer 2008, 1(1):54-59.
9. de Gruijl T.D., van den Eertwegh A.J.M., Pinedo H.M., Scheper R.J. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008, 57(10):1569-1577.
10. Hsueh E.C., Morton D.L. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003, 13(6):401-407.
11. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
12. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of Trastuzumab and Pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009, 69(24):9330-9336.
13. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 2006, 354:34-43.
14. Lin X.J., Chen X.C., Wang L., et al. Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. J Exp Clin Cancer Res 2007, 26(4):467-474.
15. Xie X., Hsu J.L., Choi M.G., et al. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 2009, 8(8):2375-2382.
16. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72(3):278-287.
17. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to senitize cancer cells to anti-cancer drugs. Curr Pharm Des 2010, 16(12):1410-1416.
18. Scappaticci F.A., Contreras A., Boswell C.A., Lewis J.S., Nolan G. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine 2003, 21(19-20):2667-2677.
19. Harandi A. Immunoplacental therapy, a potential multi-epitope cancer vaccine. Med Hypotheses 2006, 66(6):1182-1187.
20. Michallet M.C., Saltel F., Preville X., Flacher M., Revillard J.P., Genestier L. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003, 102(10):3719-3726.
21. Liebman M.A., Roche M.I., Williams B.R., Kim J., Pageau S.C., Sharon J. Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude mice. Immunol Lett 2007, 1(30):16-22.
22. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007, 117(5):1167-1174.
23. Scarberry K.E., Dickerson E.B., Zhang Z.J., Benigno B.B., McDonald J.F. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine 2010, 6(3):399-408.
24. Barrett J.S., Wagner J.G., Fisher S.J., Richard L., Wahl R.L. Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat. Cancer Res 1991, 51:3434-3444.
25. Bunn D., Lea C.K., Bevan D.J., Higgins R.M., Hendry B.M. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996, 45(1):29-32.
26. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with Trastuzumab followed by adjuvant Trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375(9712):377-384.
27. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16(1):3-15.
28. Harris J., Sengar D., Stewart T., Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 1976, 37(S2):1058-1069.